Safety
BPC-157 side effects and safety: what is known and what is not
BPC-157 side effects from the few human studies, FDA's safety concerns, the cancer and blood-vessel question, product quality risks and who programs exclude.
By Julian Caraulani · Updated October 30, 2026 · Reviewed by Dr. A. Goher, MBBS
BPC-157 side effects in people are largely unknown. Three small studies with 30 people reported no treatment-related adverse events, but a 2026 review rated that evidence very low certainty (Poolton 2026, PubMed 42885452). Long-term risks, including an unresolved cancer question, have not been studied. Compounded BPC-157 is not FDA-approved; programs start at $149 a month (price table).
Below: what the human studies report, what FDA said, the angiogenesis and cancer concern, product quality risks, who programs tell to avoid it, and what to ask your prescriber.
What the human studies report
Only three studies have given BPC-157 to people and published results. All were small, uncontrolled and led by the same author at private clinics in Florida.
| Study | Who | Adverse effects reported |
|---|---|---|
| Lee and Padgett 2021 | 16 people with knee pain, retrospective phone survey | The abstract does not report adverse events; no validated outcome tools were used |
| Lee, Walker and Ayadi 2024 | 12 women with interstitial cystitis, one treatment | "No one dropped out of the study, and no adverse events were reported" |
| Lee and Burgess 2025 | 2 adults, intravenous, three days | No measured effect on heart, liver, kidney, thyroid or blood glucose tests; no side effects reported |
The intravenous pilot reported "no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels" (Lee and Burgess 2025, PubMed 40131143). Two people over three days cannot show that a drug is safe, which the authors acknowledge by calling for further studies.
A systematic review of all three found that they "reported symptom improvement in most participants without treatment-related adverse events, but were judged to be of poor methodological quality" (Poolton 2026). An earlier review of 36 studies, 35 of them preclinical, put it more simply: "No clinical safety data were found" (Vasireddi 2025, PubMed 40756949).
What is unknown
With 30 people studied, no rare side effect could have been detected, and nobody has been followed for years. Superpower's consent form for injectable BPC-157 states it directly: "the limited human evidence means that the frequency and full range of side effects are unknown" and "An absence of reported problems does not establish safety" (Superpower BPC-157 consent).
The same form lists effects to report rather than claiming known ones. "Injections can cause pain, burning, redness, itching, swelling, bruising, bleeding, or a lump at the injection site" (Superpower BPC-157 consent). It also asks patients to report headache, nausea, dizziness, palpitations, fatigue and mood changes, while noting these are symptoms to monitor and not established effects of BPC-157.
Its other listed concerns come from preclinical findings or general drug risks: severe allergic reactions, immune reactions to the peptide or impurities, infection from contaminated product, changes in liver tests, glucose and triglycerides, and effects on clotting in both directions. Whether any of these happen in people at prescribed amounts is not known.
Price checked Oct 30 · Cancel anytime · Medication included · No email needed
Is BPC-157 linked to cancer?
There is no study showing BPC-157 causes cancer in people, and no study long enough to test it. The concern is theoretical, and it comes from how BPC-157 appears to work.
BPC-157 promotes the growth of new blood vessels (angiogenesis) in preclinical work. A 2017 study reported "the pro-angiogenic effects of BPC 157 that is associated with the increased expression, internalization of VEGFR2, and the activation of VEGFR2-Akt-eNOS signaling pathway" (Hsieh 2017, PubMed 27847966). VEGFR2 is a receptor for VEGF, a growth signal that tumors also use to build their blood supply.
Several reviews raise this as a risk:
- A 2025 literature and patent review discusses that new blood vessel formation helps tumors grow and spread, that VEGF receptors are expressed in many human cancers, and that BPC-157's pro-angiogenic action is therefore a question for cancer, while noting there are no studies relating it directly to cancer (Józwiak 2025, PubMed 40005999).
- A 2026 review of unregulated injectables lists the potential risks of BPC-157 and similar products as including "product contamination, manufacturing impurities, inaccurate dosing, pathological angiogenesis, carcinogenesis, cardiovascular stress" (Moiz 2026, PubMed 42757290).
The research group in Zagreb that has published most of the BPC-157 literature disputes this. Its 2025 review argues against "speculation of angiogenesis toward tumorigenesis" and reports anti-tumor effects in preclinical models (Sikiric 2025, PubMed 40573323). Both positions rest on preclinical work, not human data.
The one program selling BPC-157 treats it as an open question: "Whether BPC-157 could affect an existing cancer or precancerous condition is unknown" and "This is an unresolved concern, not proof that BPC-157 causes cancer" (Superpower BPC-157 consent). It excludes anyone with a cancer history (see below).
FDA's stated safety concerns
When FDA placed BPC-157 in category 2 in 2023, it gave its reasons. Compounded BPC-157 "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization." FDA added: "FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans" (FDA category 2 page).
Immunogenicity means the body may make an immune response to the peptide or its impurities. FDA's page now lists BPC-157 under substances whose nominations were withdrawn, but the safety text is unchanged.
The 28 October 2026 HHS policy allows 503A compounding without settling those questions. HHS wrote that it may revisit the policy "if, among other things, a safety signal or product quality issue arises" (Federal Register 2026-22192). Compounded drugs are not FDA-approved, and the policy is interim and can be withdrawn; status checked on 30 October 2026. Details in is BPC-157 legal.
Quality risks of unregulated BPC-157
Much of the real-world risk may come from the product rather than the peptide. A 2025 review warned that "Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety" (Vasireddi 2025). A 2026 orthopaedic review added that commercial products "raise concerns regarding identity, purity, concentration, sterility, and manufacturing consistency" (Tham 2026, PubMed 42937313).
The HHS policy adds conditions for pharmacies: ingredients "must come from FDA-registered manufacturers that meet current good manufacturing practice requirements," and each lot needs a certificate of analysis covering "identity, potency, impurities and contaminants" (Superpower summary of the policy). Research-use vials sold without a prescription carry none of these requirements. See compounded peptide safety and research vs prescription peptides.
Who should avoid BPC-157
BPC-157 has no FDA label, so there is no official list of contraindications. Superpower's consent form sets its own exclusions (Superpower BPC-157 consent):
| Group | What the program says |
|---|---|
| Under 18 | Excluded |
| Pregnancy | "You are pregnant, breastfeeding, or attempting to conceive" is an exclusion |
| Cancer history | "You have any personal history of cancer, regardless of cancer type, stage, or time since diagnosis or treatment" is an exclusion, as is a precancerous condition under surveillance or suspected cancer |
| Allergy | Known allergy to BPC-157 or an ingredient, or a serious reaction to a previous dose |
| Blood thinners | "Tell your Healthcare Provider if you take anticoagulants or antiplatelet medications" |
| Other conditions to disclose | Liver or kidney disease, diabetes, bleeding or clotting disorders, immune conditions, active infection, planned surgery |
| Tested athletes | "BPC-157 is prohibited at all times under the World Anti-Doping Agency Prohibited List, including during and outside competition" |
These are one program's rules, not a regulator's. A different prescriber may set different ones, which is a reason to ask.
When to get help
Superpower's form tells patients to seek emergency care for difficulty breathing, swelling of the face, lips, tongue or throat, collapse, chest pain or severe bleeding. It asks patients to hold doses and get checked for a spreading, hot or draining injection site, fever, black or bloody stools, yellowing skin or eyes, or a new lump (Superpower BPC-157 consent). You can report side effects to FDA through MedWatch.
What to ask your prescriber
- Given my history, including any cancer, clotting or liver issue, why is BPC-157 reasonable for me?
- Which labs will you check, and when?
- Which pharmacy compounds it, and can I see the certificate of analysis?
- Is the product BPC-157 alone? Blends are outside the HHS policy.
- What should make me stop, and how do I report a reaction?
- What established treatments should I try first or alongside?
Your prescriber sets the form and amount; we do not publish doses. For the basics, read what BPC-157 is; for prices, the BPC-157 cost guide.
FAQ
What are the side effects of BPC-157?
The full list is unknown. The three published human studies, with 30 people in total, reported no treatment-related adverse events, but they were small, short and uncontrolled. Programs ask patients to watch for injection-site pain, redness, swelling or bruising, and to report headache, nausea, dizziness or palpitations, without claiming these are established effects of BPC-157.
Is BPC-157 safe?
Safety in people has not been established. FDA said in its 2023 review that it lacked sufficient information to know whether BPC-157 would cause harm in humans, and flagged immune reactions and impurities. A 2026 systematic review rated the human evidence very low certainty. Prescription programs screen and monitor patients, but that does not make the drug proven safe.
Does BPC-157 cause cancer?
No study shows BPC-157 causes cancer in people, and none has run long enough to test it. The concern is theoretical: BPC-157 promotes blood vessel growth through VEGF signaling in preclinical studies, and tumors depend on new blood vessels. Some reviewers flag this as a risk; the main BPC-157 research group disputes it. Superpower excludes anyone with a cancer history.
What are the main BPC-157 risks?
The main risks named in the literature and by FDA are immune reactions, impurities and poorly characterized product, infection or contamination from unregulated vials, possible effects on clotting and liver tests seen in preclinical work, and the unresolved cancer question. Unknown long-term effects are a risk in themselves, since nobody has been followed for years.
Can BPC-157 affect bleeding or blood thinners?
Possibly, but nobody knows. Superpower's consent form says preclinical studies showed changes in clotting measures in different directions, with human risks not established. Its form asks patients to tell the prescriber about anticoagulants or antiplatelet drugs such as warfarin, apixaban, aspirin or clopidogrel, and about planned surgery. Raise these before starting.
Who should not take BPC-157?
Superpower excludes people under 18, anyone pregnant, breastfeeding or trying to conceive, anyone with a personal history of cancer or a precancerous condition under surveillance, and anyone allergic to the product. Tested athletes face anti-doping rules. People with liver, kidney, clotting or immune conditions need extra review first.
Compare prescription BPC-157 programs on screening, labs and monitoring on our best peptide programs page, or see every plan on the BPC-157 price table.